Sep. 9 at 1:50 PM
Noble Capital Markets Research Report: Gyre Therapeutics, Inc (
$GYRE) – Positioned To End YE2025 With Strong Products and Pipeline Development
Gyre Has Made Strong YTD Progress. Gyre has made significant progress during the first three quarters of FY2025 that we believe positions the company for a strong year-end. These developments include continued sales growth from two products introduced in 1H25, an application for Hydronidone approval in China, and the start of a Phase 2 clinical trial for Hydronidone in the US. The company also announced the appointment of Dr. Han Ying as the new CEO, a member of the Board of Directors since January 2025.
Read more: https://www.channelchek.com/news-channel/gyre-therapeutics-inc-gyre-positioned-to-end-ye2025-with-strong-products-and-pipeline-development